Lung Cancer Therapeutics Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Market Dynamics of Lung Cancer Therapeutics Market Analysis

Growth Drivers

  • The strong prevalence of lung cancer is notably driving market growth
  • Rising pollution due to rapid industrialization increases the incidences of lung cancer  

Restraints

  • Regional disparities in treatment will hamper the market for lung cancer therapeutics  

Trends

  • The arrival of nanomedicine to treat lung cancer  

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Lung Cancer Therapeutics Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Global Lung Cancer Therapeutics Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxxxxxxxxxxxxxx
North Americaxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx
Europexxxxxxxxxxxxxxxx
United Kingdomxxxxxxxxxxxxxxxx
Francexxxxxxxxxxxxxxxx
Germanyxxxxxxxxxxxxxxxx
Italyxxxxxxxxxxxxxxxx
Russiaxxxxxxxxxxxxxxxx
Spainxxxxxxxxxxxxxxxx
Swedenxxxxxxxxxxxxxxxx
Denmarkxxxxxxxxxxxxxxxx
Switzerlandxxxxxxxxxxxxxxxx
Luxembourgxxxxxxxxxxxxxxxx
Rest of Europexxxxxxxxxxxxxxxx
Asia Pacificxxxxxxxxxxxxxxxx
Chinaxxxxxxxxxxxxxxxx
Japanxxxxxxxxxxxxxxxx
South Koreaxxxxxxxxxxxxxxxx
Indiaxxxxxxxxxxxxxxxx
Australiaxxxxxxxxxxxxxxxx
Singaporexxxxxxxxxxxxxxxx
Taiwanxxxxxxxxxxxxxxxx
South East Asiaxxxxxxxxxxxxxxxx
Rest of APACxxxxxxxxxxxxxxxx
South Americaxxxxxxxxxxxxxxxx
Brazilxxxxxxxxxxxxxxxx
Argentinaxxxxxxxxxxxxxxxx
Colombiaxxxxxxxxxxxxxxxx
Peruxxxxxxxxxxxxxxxx
Chilexxxxxxxxxxxxxxxx
Rest of South Americaxxxxxxxxxxxxxxxx
Middle Eastxxxxxxxxxxxxxxxx
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxxxxxx
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxxxxxx
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxxxxxx
Africaxxxxxxxxxxxxxxxx
East Africaxxxxxxxxxxxxxxxx
West Africaxxxxxxxxxxxxxxxx
North Africaxxxxxxxxxxxxxxxx
South Africaxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Lung Cancer Therapeutics Disease Type Segment Analysis Non-small cell lung cancer Small cell lung cancer Based on the disease type lung cancer therapeutics market is divided into non-small cell lung cancer and small cell lung cancer. The non-stem cell lung cancer segment dominated the market growth in 2024 and is projected to be the fastest-growing segment during the forecast period, 2024-2031. Because non-small cell lung cancer (NSCLC) begins at the cellular level, lung cancer cells proliferate quickly and unpredictably. It is more common in women and typically develops in the outer part of the lungs. After the diagnosis of NSCLC, the stage of cancer is determined. Approximately 90% of cases of non-small cell lung cancer are caused by smoking. Patients with NSCLC have a 5-year survival rate of 63%. To treat NSCLC, patients may combine radiation therapy, chemotherapy, surgery, and targeted therapy. The most prevalent kind of lung cancer, accounting for around 80% of all lung malignancies, is non-small cell lung cancer. • For instance, in May 2021, Janssen Pharmaceutical reported that the U.S. FDA granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. Such product approvals are also adding to the growth of the market and are likely to do the same over the forecast period. (Source:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications) • For instance, in October 2021, United States FDA approved the immunotherapy drug atezlizumab (Tecentriq) as an additional treatment after surgery and chemotherapy for some patients with non-small cell lung cancer (NSCLC). The recent approval of drugs for the treatment of non-small cell lung cancer is likely to boost the growth of the market. (Source:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer)

Non-small cell lung cancer Lung Cancer Therapeutics Market Analysis
XX
Non-small cell lung cancer Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Small cell lung cancer Lung Cancer Therapeutics Market Analysis
XX
Small cell lung cancer Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape: Lung Cancer Therapeutics Market

By expanding their market presence and attracting new customers, the industry's players focus on leveraging the present business opportunities in the lung cancer therapeutics market. Market participants are bringing new products to the market. Eli Lilly and Company, Hoffmann-La Roche, Merck & Co, Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie, Inc., Johnson & Johnson, Amgen Inc., Novartis AG. and other significant players are among the important participants. Smart nanoparticles and a unique surgical method are used in a recently disclosed, efficacious, and promising lung cancer therapeutic strategy that targets lung tumors (Advanced Therapeutics). Additionally, they are establishing partnerships, manufacturing facilities, and distribution networks to meet the expanding need for electric vehicles across a range of geographic areas.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Pfizer••• ••• ••• •••
Roche••• ••• ••• •••
Merck••• ••• ••• •••
AstraZeneca••• ••• ••• •••
Sanofi-Aventis••• ••• ••• •••
Eli Lilly and Company••• ••• ••• •••
Abbott••• ••• ••• •••
Akebia Therapeutics••• ••• ••• •••
Agennix AG••• ••• ••• •••
Allergan Inc.••• ••• ••• •••
Teva Pharmaceutical Industries Ltd.••• ••• ••• •••
Abbvie Inc.••• ••• ••• •••
Johnson & Johnson••• ••• ••• •••
Amgen Inc.••• ••• ••• •••
Novartis AG••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

Market Research Database with comprehensive market size, industry analysis, growth drivers, market trends, key player analysis, country-level insights, market segmentation, PESTEL analysis, and strategic consulting. Download a free sample with data verified by Supriya Yadav.

Introduction of the Lung Cancer Therapeutics

Lung cancer is a kind of cancer that starts as a growth of cells in the lungs. The lungs are two spongy organs in the chest that control breathing. Lung cancer is the leading cause of cancer deaths worldwide. People who smoke have the greatest risk of lung cancer. The risk of lung cancer increases with the length of time and number of cigarettes smoked. Quitting smoking, even after smoking for many years, significantly lowers the chances of developing lung cancer. Lung cancer also can happen in people who have never smoked.
Factors driving the market growth include the increasing prevalence of lung cancer, rising pollution due to rapid industrialization, growth in the number of smokers, and increasing funding for the R&D of new drugs. The lung cancer therapeutics market is moderately concentrated in nature due to the presence of companies operating globally as well as regionally. For the inhalation treatment of lung cancer, a wide range of nanocarriers have been studied, including liposomes, micelles, polymeric NPs, inorganic NPs, and solid lipid NPs. Different medication classes combat cancer cells in different ways. A personalized treatment strategy will be suggested by the oncologist for each patient.

Analyst Conclusion

Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. Market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Lung Cancer Therapeutics Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Pfizer, Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Abbott, Akebia Therapeutics, Agennix AG, Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie Inc., Johnson & Johnson, Amgen Inc., Novartis AG and others are profiled in the report.
Segments include Disease Type, Treatment and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Lung Cancer Therapeutics Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Disease TypeNon-small cell lung cancer, Small cell lung cancer
TreatmentSurgery, Chemotherapy, Radiation therapy, Immunotherapy, Targeted therapy
End-UserHospitals, Clinics, Cancer Research Centers, Laboratories
List of CompetitorsPfizer, Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Abbott, Akebia Therapeutics, Agennix AG, Allergan Inc., Teva Pharmaceutical Industries Ltd., Abbvie Inc., Johnson & Johnson, Amgen Inc., Novartis AG

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Global Lung Cancer Therapeutics Market Analysis by Key Players
      • 1.1.2 Segment Market Analysis by Key Players
      • 1.1.3 Top Players Ranking 2024
      • 1.1.4 New Product Launch Analysis
      • 1.1.5 Industry Mergers and Acquisition Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Pfizer
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 Financials (Subject to data availability)
        • 1.2.1.4 R&D Investment (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Roche
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 Financials (Subject to data availability)
        • 1.2.2.4 R&D Investment (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Merck
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 Financials (Subject to data availability)
        • 1.2.3.4 R&D Investment (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 AstraZeneca
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 Financials (Subject to data availability)
        • 1.2.4.4 R&D Investment (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Sanofi-Aventis
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 Financials (Subject to data availability)
        • 1.2.5.4 R&D Investment (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Eli Lilly and Company
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 Financials (Subject to data availability)
        • 1.2.6.4 R&D Investment (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Abbott
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 Financials (Subject to data availability)
        • 1.2.7.4 R&D Investment (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Akebia Therapeutics
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 Financials (Subject to data availability)
        • 1.2.8.4 R&D Investment (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Agennix AG
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 Financials (Subject to data availability)
        • 1.2.9.4 R&D Investment (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Allergan Inc.
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 Financials (Subject to data availability)
        • 1.2.10.4 R&D Investment (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Teva Pharmaceutical Industries Ltd.
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 Financials (Subject to data availability)
        • 1.2.11.4 R&D Investment (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis
      • 1.2.12 Abbvie Inc.
        • 1.2.12.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.12.2 Business Overview
        • 1.2.12.3 Financials (Subject to data availability)
        • 1.2.12.4 R&D Investment (Subject to data availability)
        • 1.2.12.5 Product Types Specification
        • 1.2.12.6 Business Strategy
        • 1.2.12.7 Recent Developments
        • 1.2.12.8 Management Change
        • 1.2.12.9 S.W.O.T Analysis
      • 1.2.13 Johnson & Johnson
        • 1.2.13.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.13.2 Business Overview
        • 1.2.13.3 Financials (Subject to data availability)
        • 1.2.13.4 R&D Investment (Subject to data availability)
        • 1.2.13.5 Product Types Specification
        • 1.2.13.6 Business Strategy
        • 1.2.13.7 Recent Developments
        • 1.2.13.8 Management Change
        • 1.2.13.9 S.W.O.T Analysis
      • 1.2.14 Amgen Inc.
        • 1.2.14.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.14.2 Business Overview
        • 1.2.14.3 Financials (Subject to data availability)
        • 1.2.14.4 R&D Investment (Subject to data availability)
        • 1.2.14.5 Product Types Specification
        • 1.2.14.6 Business Strategy
        • 1.2.14.7 Recent Developments
        • 1.2.14.8 Management Change
        • 1.2.14.9 S.W.O.T Analysis
      • 1.2.15 Novartis AG
        • 1.2.15.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.15.2 Business Overview
        • 1.2.15.3 Financials (Subject to data availability)
        • 1.2.15.4 R&D Investment (Subject to data availability)
        • 1.2.15.5 Product Types Specification
        • 1.2.15.6 Business Strategy
        • 1.2.15.7 Recent Developments
        • 1.2.15.8 Management Change
        • 1.2.15.9 S.W.O.T Analysis

  • Chapter 2. Global Lung Cancer Therapeutics Market Analysis

    • 2.1 Global Lung Cancer Therapeutics Market Analysis
    • 2.2 Global Lung Cancer Therapeutics Market Analysis by Region
    • 2.3 Global Lung Cancer Therapeutics Market Analysis by Disease Type
    • 2.4 Global Lung Cancer Therapeutics Market Analysis by Treatment
    • 2.5 Global Lung Cancer Therapeutics Market Analysis by End-User
    • 2.6 Global Lung Cancer Therapeutics Market Analysis by Key Players

  • Chapter 3. North America Lung Cancer Therapeutics Market Analysis

    • 3.1 North America Lung Cancer Therapeutics Market Analysis
    • 3.2 North America Lung Cancer Therapeutics Market Analysis by Country
    • 3.3 North America Lung Cancer Therapeutics Market Analysis by Disease Type
    • 3.4 North America Lung Cancer Therapeutics Market Analysis by Treatment
    • 3.5 North America Lung Cancer Therapeutics Market Analysis by End-User
    • 3.6 North America Lung Cancer Therapeutics Market Analysis by Key Players

  • Chapter 4. Europe Lung Cancer Therapeutics Market Analysis

    • 4.1 Europe Lung Cancer Therapeutics Market Analysis
    • 4.2 Europe Lung Cancer Therapeutics Market Analysis by Country
    • 4.3 Europe Lung Cancer Therapeutics Market Analysis by Disease Type
    • 4.4 Europe Lung Cancer Therapeutics Market Analysis by Treatment
    • 4.5 Europe Lung Cancer Therapeutics Market Analysis by End-User
    • 4.6 Europe Lung Cancer Therapeutics Market Analysis by Key Players

  • Chapter 5. Asia Pacific Lung Cancer Therapeutics Market Analysis

    • 5.1 Asia Pacific Lung Cancer Therapeutics Market Analysis
    • 5.2 Asia Pacific Lung Cancer Therapeutics Market Analysis by Country
    • 5.3 Asia Pacific Lung Cancer Therapeutics Market Analysis by Disease Type
    • 5.4 Asia Pacific Lung Cancer Therapeutics Market Analysis by Treatment
    • 5.5 Asia Pacific Lung Cancer Therapeutics Market Analysis by End-User
    • 5.6 Asia Pacific Lung Cancer Therapeutics Market Analysis by Key Players

  • Chapter 6. South America Lung Cancer Therapeutics Market Analysis

    • 6.1 South America Lung Cancer Therapeutics Market Analysis
    • 6.2 South America Lung Cancer Therapeutics Market Analysis by Country
    • 6.3 South America Lung Cancer Therapeutics Market Analysis by Disease Type
    • 6.4 South America Lung Cancer Therapeutics Market Analysis by Treatment
    • 6.5 South America Lung Cancer Therapeutics Market Analysis by End-User
    • 6.6 South America Lung Cancer Therapeutics Market Analysis by Key Players

  • Chapter 7. Middle East Lung Cancer Therapeutics Market Analysis

    • 7.1 Middle East Lung Cancer Therapeutics Market Analysis
    • 7.2 Middle East Lung Cancer Therapeutics Market Analysis by Country
    • 7.3 Middle East Lung Cancer Therapeutics Market Analysis by Disease Type
    • 7.4 Middle East Lung Cancer Therapeutics Market Analysis by Treatment
    • 7.5 Middle East Lung Cancer Therapeutics Market Analysis by End-User
    • 7.6 Middle East Lung Cancer Therapeutics Market Analysis by Key Players

  • Chapter 8. Africa Lung Cancer Therapeutics Market Analysis

    • 8.1 Africa Lung Cancer Therapeutics Market Analysis
    • 8.2 Africa Lung Cancer Therapeutics Market Analysis by Country
    • 8.3 Africa Lung Cancer Therapeutics Market Analysis by Disease Type
    • 8.4 Africa Lung Cancer Therapeutics Market Analysis by Treatment
    • 8.5 Africa Lung Cancer Therapeutics Market Analysis by End-User
    • 8.6 Africa Lung Cancer Therapeutics Market Analysis by Key Players

  • Chapter 9. Disease Type Analysis

    • 9.1 Non-small cell lung cancer
      • 9.1.1 Global Non-small cell lung cancer Market
      • 9.1.2 Global Non-small cell lung cancer Market by Region
    • 9.2 Small cell lung cancer
      • 9.2.1 Global Small cell lung cancer Market
      • 9.2.2 Global Small cell lung cancer Market by Region

  • Chapter 10. Treatment Analysis

    • 10.1 Surgery
      • 10.1.1 Global Surgery Market
      • 10.1.2 Global Surgery Market by Region
    • 10.2 Chemotherapy
      • 10.2.1 Global Chemotherapy Market
      • 10.2.2 Global Chemotherapy Market by Region
    • 10.3 Radiation therapy
      • 10.3.1 Global Radiation therapy Market
      • 10.3.2 Global Radiation therapy Market by Region
    • 10.4 Immunotherapy
      • 10.4.1 Global Immunotherapy Market
      • 10.4.2 Global Immunotherapy Market by Region
    • 10.5 Targeted therapy
      • 10.5.1 Global Targeted therapy Market
      • 10.5.2 Global Targeted therapy Market by Region

  • Chapter 11. End-User Analysis

    • 11.1 Hospitals
      • 11.1.1 Global Hospitals Market
      • 11.1.2 Global Hospitals Market by Region
    • 11.2 Clinics
      • 11.2.1 Global Clinics Market
      • 11.2.2 Global Clinics Market by Region
    • 11.3 Cancer Research Centers
      • 11.3.1 Global Cancer Research Centers Market
      • 11.3.2 Global Cancer Research Centers Market by Region
    • 11.4 Laboratories
      • 11.4.1 Global Laboratories Market
      • 11.4.2 Global Laboratories Market by Region

  • Chapter 12. Qualitative Analysis (Subject to Data Availability)

    • 12.1 Market Drivers
    • 12.2 Market Restraints
    • 12.3 Market Trends
    • 12.4 Market Opportunity
    • 12.5 Technological Road Map (Subject to Data Availability)
    • 12.6 Product Life Cycle (Subject to Data Availability)
    • 12.7 Customer and Buyer Behavior Analysis
      • 12.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 12.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 12.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 12.7.4 Pricing, Affordability & Value Perception Analysis
      • 12.7.5 Customer Segmentation & Demand Pattern Analysis
    • 12.8 PESTEL Analysis
      • 12.8.1 Political Factors
      • 12.8.2 Economic Factors
      • 12.8.3 Social Factors
      • 12.8.4 Technological Factors
      • 12.8.5 Legal Factors
      • 12.8.6 Environmental Factors
    • 12.9 Industrial Chain Analysis (Subject to Data Availability)
      • 12.9.1 Industry Chain Analysis
      • 12.9.2 Manufacturing Cost Analysis
      • 12.9.3 Supply Side Analysis
        • 12.9.3.1 Raw Material Analysis
        • 12.9.3.2 Raw Material Procurement Analysis
        • 12.9.3.3 Raw Material Price Trend Analysis
    • 12.10 Porter’s Five Forces Analysis
      • 12.10.1 Bargaining Power of Suppliers
      • 12.10.2 Bargaining Power of Buyers
      • 12.10.3 Threat of New Entrants
      • 12.10.4 Threat of Substitutes
      • 12.10.5 Degree of Competition
    • 12.11 Patent Analysis (Subject to Data Availability)
    • 12.12 ESG Analysis
    • 12.13 Geopolitical Outlook
      • 12.13.1 Global Power Realignment & Strategic Alliances
      • 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 12.13.3 International Trade Relations & Market Access Environment
      • 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 12.13.6 Technology Sovereignty & Digital Geopolitics
      • 12.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 12.14 AI & Market Transformation
      • 12.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 12.14.2 AI-Driven Transformation of Industry Value Chain
      • 12.14.3 Evolution of Business Models & Revenue Streams
      • 12.14.4 AI-Driven Product, Service & Innovation Transformation
      • 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 13. TOP 10 Country Analysis

    • 13.1 Country 1
    • 13.2 Country 2
    • 13.3 Country 3
    • 13.4 Country 4
    • 13.5 Country 5
    • 13.6 Country 6
    • 13.7 Country 7
    • 13.8 Country 8
    • 13.9 Country 9
    • 13.10 Country 10

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Lung Cancer Therapeutics Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 15+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Latest News about Lung Cancer Therapeutics Market

 16 Jul 2024 pharmaceutical-technology.com

AstraZeneca’s Tagrisso gains approval in Canada for NSCLC

AstraZeneca has obtained Health Canada’s Notice of Compliance (NOC) for Tagrisso (osimertinib) along with pemetrexed and platinum-based chemotherapy, to treat epidermal growth factor receptor (EGFR)-mutated lung cancer.
The approval is meant to be used as a first-line therapy for individuals with certain EGFR mutations who have locally progressed or metastatic non-small cell lung cancer (NSCLC). The FLAURA2 Phase III clinical study, which showed a 38% decrease in the risk of disease progression or mortality when Tagrisso was paired with chemotherapy as opposed to Tagrisso monotherapy, is the basis for Health Canada's decision. Five hundred fifty-seven patients from 150 centers in 20 countries—three in Canada—were enrolled in the open-label, randomized, multicenter, international trial. Patients receiving combination treatment had a median progression-free survival (PFS) of 25.5 months, which was 8.8 months longer than that of Tagrisso monotherapy patients at 16.7 months.

Read the source

Sources from the Pharma & Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Lung Cancer Therapeutics Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the lung cancer therapeutics market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.